Synopsis

Differential Target Multiplexed^TM spinal cord stimulation (SCS) is an established therapy that has shown superior back pain relief to traditional SCS.1 This study evaluates efficacy, device longevity, and recharge requirements of a reduced DTMTM derivative in patients with severe back and leg pain to understand opportunities to tailor therapy based on patient profiles and estimate device longevity and recharge requirements. Subjects were trialed with the DTMTM derivative and those who reported ≥50% improvement in overall pain were eligible for implant. Implanted subjects have reported therapy satisfaction and improved quality of life through 3-months and sustained overall pain relief through 6-months.

Disclosures

This study was funded by Medtronic.
K. Amirdelfan reports SAB at Nevro, Medtronic, and Nalu, consulting fees from Biotronik, Nalu, Nevro, Saluda, and Medtronic, research grants to institution from Nevro, Biotronik, and reports minor options at Nalu; M. Esposito reports SAB and consulting fees from Abbott, Biotronik, Boston Scientific, Flowonix, Inspan, Medtronic, Nevro, and Stimwave; M. Fishman reports research grants to institution from Abbott, Biotronik, Boston Scientific, Medtronic, Nalu Medical, SGX Medical, and Thermaquil, consulting fees from Abbott, Biotronik, Medtronic, and Nevro, faculty appointment with Abbott and Medtronic, and stock/stock options at Celeri Health, and Thermaquil; K. Gatzinsky reports consultancy (Teaching/training) at Medtronic, Boston Scientific, Abbott, Nevro, and SAB at Medtronic and Boston Scientific;. P.K. Grewal reports SAB at Medtronic; R. Justiz reports consulting fees from Medtronic; J.W. Kallewaard reports SAB at Abbott, Medtronic, Saluda and Boston Scientific; D. Provenzano reports consulting fees from Avanos, Boston Scientific, Medtronic, Nevro, SI Bone, and Wise, and research grants to institution from Avanos, Boston Scientific, Medtronic, Nevro, Stimgenics, and Abbott; T. White reports consulting fees from Medtronic; T. Bromberg reports relationships with Medtronic and Saluda; A. Calodney reports relationships with Boston Scientific, Medtronic, Nevro, and PainTeq; T. Schmidt reports relationships with Boston Scientific and Medtronic; J. Peacock and B. Shah report nothing to disclose; L. Davies, K. Noel, A. Cleland, M. LaRue, and C. Porritt are all employees of Medtronic.

Michael Fishman MD, MBA

Anesthesiologist and Interventional Pain Medicine Specialist, Center for Interventional Pain and Spine

Appearances